Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor

Bone Marrow Transplant. 1996 Jul;18(1):47-52.

Abstract

The characteristics of PBSC mobilized with GM-CSF, which has been shown to augment monocyte/macrophage (Mo/Mx) antitumor and accessory activities, were evaluated. Patients with metastatic cancers were treated with GM-CSF at 5 micrograms/kg sc, days 1 to 7; leukaphereses were performed on days 6 and 7. A mean of 3.3 x 10(10) mononuclear cells were collected, 59% of which were lymphoid and 32%, monocytoid. Spontaneous Mo/Mx tumor cell cytotoxicity was not detectable in the leukapheresis product, either before or after cryopreservation; Mo/Mx tumor cell cytotoxicity, however, was inducible in vitro with IFN-gamma. Likewise, spontaneous lymphocyte cytotoxicity was not detectable in the leukapheresis product; lymphokine-activated killer cell activity was inducible in vitro with IL-2. Whereas lymphoproliferative responses to tetanus toxoid of cryopreserved PBSC were less than that of freshly collected PBSC, the capacity of Mo/Mx from cryopreserved PBSC to function as accessory cells in the lymphoproliferative response was maintained. These results indicate that significant numbers of immune cells can be mobilized with GM-CSF alone. Cryopreserved, GM-CSF-mobilized PBSC do not demonstrate spontaneous antitumor cytolytic activity; however, accessory activity is present and antitumor cytolytic activity mediated by both monocytoid and lymphoid cells is inducible.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antigen-Presenting Cells / drug effects
  • Antigen-Presenting Cells / immunology*
  • Antigens, CD / analysis
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Blood Preservation
  • Bone Marrow / drug effects*
  • Bone Marrow / pathology
  • Bone Marrow Diseases / chemically induced
  • Combined Modality Therapy
  • Cryopreservation
  • Cytotoxicity, Immunologic / drug effects
  • Dacarbazine / administration & dosage
  • Dacarbazine / adverse effects
  • Dacarbazine / pharmacology
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Doxorubicin / pharmacology
  • Female
  • Granulocyte-Macrophage Colony-Stimulating Factor* / pharmacology*
  • Hematopoietic Stem Cells / drug effects
  • Hematopoietic Stem Cells / immunology
  • Hematopoietic Stem Cells / physiology*
  • Humans
  • Ifosfamide / administration & dosage
  • Ifosfamide / adverse effects
  • Ifosfamide / pharmacology
  • Interferon-gamma / pharmacology
  • Interleukin-2 / pharmacology
  • Leukapheresis
  • Macrophages / immunology
  • Macrophages / pathology
  • Male
  • Middle Aged
  • Monocytes / immunology
  • Monocytes / pathology
  • Neoplasms / drug therapy
  • Neoplasms / immunology*
  • Neoplasms / pathology
  • Neoplasms / therapy
  • Recombinant Proteins / pharmacology
  • Tetanus Toxoid / immunology
  • Time Factors
  • Tumor Cells, Cultured

Substances

  • Antigens, CD
  • Interleukin-2
  • Recombinant Proteins
  • Tetanus Toxoid
  • sargramostim
  • Dacarbazine
  • Doxorubicin
  • Interferon-gamma
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Ifosfamide